REVEALED: Gilead - The Real Truth

Gilead to Pay Texas $45 Million Over Claims Its Free Nurse Program Steered Medicaid Prescriptions, Denies Wrongdoing

Gilead Sciences will pay Texas $45 million to resolve allegations that free nursing and reimbursement services improperly influenced Medicaid prescriptions, while denying wrongdoing and liability.

Medical Daily · Oct 28

3 Defensive Stocks to Buy as the AI Selloff Rattles Wall Street

The recent AI sell-off shows why diversification matters. Here are three stocks that can help investors diversify their portfolios.

Barchart · Oct 23

Gilead's Experimental Ulcerative Colitis Pill Beat Placebo by 23 Points on Remission, but Long-Term Safety Data Are Pending

Gilead's experimental pill emvistegrast beat placebo by 23 percentage points on ulcerative colitis remission in a Phase 2 trial, but long-term data are pending.

Medical Daily · Oct 21

Gilead Wins Approval for a Single HIV Tablet Aimed at Patients Taking Handfuls of Pills Each Day

FDA approved Bixlenvo, a once-daily tablet combining bictegravir and lenacapavir for virologically suppressed adults on complex HIV regimens.

Medical Daily · Sep 1

FDA Decision Due Thursday on a Two-Drug HIV Pill Designed to Simplify Complex Daily Regimens

The FDA faces an August 27 target date on Gilead's bictegravir and lenacapavir tablet for adults already virally suppressed on HIV therapy.

Medical Daily · Aug 24

Meet Serena Joy, 'The Handmaid's Tale' Villain Behind Olivia Rodrigo's Most Outspoken Song

Olivia Rodrigo's surprise single 'Serena Joy' critiques complicity and supports reproductive rights, drawing inspiration from Margaret Atwood's 'The Handmaid's Tale'. Proceeds benefit multiple reproductive health organisations.

International Business Times UK · Aug 24

Once-Weekly HIV Pill Held Viral Suppression as Well as Daily Treatment in Two Phase 3 Trials

Two phase 3 trials found that a weekly islatravir and lenacapavir tablet matched daily HIV therapy at 48 weeks. Here is what the data show.

Medical Daily · Aug 5

California Supreme Court Rules Gilead Had No Legal Duty to Bring a Newer HIV Drug to Market Sooner

California's high court rejected a duty-to-innovate claim from about 24,000 HIV patients. Here is what the ruling does and does not decide.

Medical Daily · Aug 5

Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead Sciences has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

Barchart · Jul 30

The FDA Approves the First-Ever Hepatitis Delta Treatment: Here's Why Hepatitis B Patients Should Get Tested

FDA approved bulevirtide May 22, 2026 — the first-ever Hepatitis Delta treatment. About 80,000 Americans have HDV. Here's who should ask for testing and what the approval means.

Medical Daily · Jun 30